3sbio

3SBio, a pharmaceutical preparation manufacturer based in China, has reported its carbon emissions for several years, focusing on Scope 1 and Scope 2.

For the reporting year 2024, 3SBio reported a Scope 1 and 2 total of approximately 69.1 million kg CO2e (market-based). This breaks down to approximately 13.3 million kg CO2e for Scope 1 and about 55.8 million kg CO2e for Scope 2 (market-based).

In 2023, the company's combined Scope 1 and 2 emissions were approximately 60.6 million kg CO2e (location-based). Scope 1 emissions for this year were around 11.7 million kg CO2e, and Scope 2 emissions were approximately 49.0 million kg CO2e (location-based).

For 2022, 3SBio's Scope 1 and 2 emissions totalled approximately 45.9 million kg CO2e (location-based), with Scope 1 at about 7.3 million kg CO2e and Scope 2 at approximately 38.6 million kg CO2e (location-based).

Earlier reports include:

• 2021: Total Scope 1 and 2 emissions were approximately 56.2 million kg CO2e.
• 2020: Total Scope 1 and 2 emissions were approximately 47.7 million kg CO2e.
• 2019: Total emissions (Scope 1 and 2) were approximately 48.7 million kg CO2e.

3SBio's disclosures indicate that Scope 3 emissions, such as those from purchased goods and services, are not yet reported. The company has not publicly disclosed specific reduction targets or commitments, nor are there any indications of alignment with initiatives like the Science Based Targets initiative (SBTi) or the Climate Pledge based on the provided information.